MedTech CDMO: Market and M&A Global Trends in 2024
Tuesday, February 27, 2024 (12:00 PM - 1:00 PM) (EST)
Despite a strenuous past year in the medtech industry, the global medtech contract development and manufacturing (CDMO) market has continued to grow steadily, reaching $81.5B in 2023. Over half of worldwide industry revenues can be attributed to the resilient performance of more than 600 CDMOs across European and US markets.
This webinar will investigate the current state of the global medtech CDMO industry and highlight Europe as a promising frontier for consolidation. Attendees will get key insights surrounding this dynamic market, including:
- The market trends that impact the performance of global medtech CDMOs today
- An assessment of Western Europe’s CDMO landscape that identifies the region’s core capabilities and end markets
- A 2024 outlook for medtech CDMOs that contextualizes mergers and acquisitions (M&A) activity from 2023 with expected market opportunities and risks
During this webinar the attendees will also be able to download the Alira Health’s annual 2024 Global Medtech Contract Manufacturing (CDMO) Report.
Carlo Stimamiglio has over 15 years of experience in deal making roles and a global track record of healthcare transactions. After early experiences in asset management and corporate finance roles, Carlo joined Alira Health in 2014 and he has developed multiple practices in the Transaction Advisory Division. Carlo is a recognized research author and opinion leader in the global pharmaceutical and medical device CDMO markets, fields in which he regularly advises M&A transactions. Carlo leads Alira Health’s global MedTech investment banking practice, supporting companies in the structuring and execution of financing, M&A and global licensing deals. Carlo’s role includes leadership of Alira Health’s Corporate M&A activities at Alira Health and has led more than 10 corporate acquisitions since 2018. Carlo holds a MS in Finance from the University of Verona and an MBA from IE Business School. He is a licensed investment banking representative, holding FINRA Series 79 and 63 licenses.
Sofia focuses on MedTech M&A deals, capital raisings, and pharmaceutical licensing. She holds a MSc in Management from ESSEC Business School, in France, with a major in Strategic Consulting and Therapeutic Innovation and a BSc in Business Economics from Bocconi University, in Italy. She is an investment banking representative, holding FINRA Series 79 license.